<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00958269</url>
  </required_header>
  <id_info>
    <org_study_id>PHX1149-PROT306</org_study_id>
    <nct_id>NCT00958269</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo- and Sitagliptin-Controlled, Multi-Center Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment Including Subjects on Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phenomix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Phenomix</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of dutogliptin in Type 2
      diabetic subjects with moderate or severe renal impairment.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Technical/operational issues
  </why_stopped>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">November 2011</completion_date>
  <primary_completion_date type="Anticipated">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of dutogliptin as assessed by analysis of AEs/SAEs, laboratory data, vital signs, and ECGs</measure>
    <time_frame>Day 1 through day 182 (end of the 26-week, double-blind, placebo-controlled period) and through Day 364 (end of the 26-week, sitagliptin-controlled period of the study)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of HbA1c</measure>
    <time_frame>Day 1 to Day 182</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of fasting plasma glucose</measure>
    <time_frame>Day 1 to Day 182</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma dutogliptin levels</measure>
    <time_frame>Days 1, 198 and 182</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per cent ex vivo DPP4 inhibition after drug dosing</measure>
    <time_frame>Days 1, 98, and 182</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>dutogliptin (double-blind, placebo-controlled period)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>weeks 1-26</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dutogliptin (single-blind, active-controlled period)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>weeks 27-52</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo (double-blind, placebo-controlled period)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>weeks 1-26</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo (single-blind, active-controlled period)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>weeks 27-52</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sitagliptin (single-blind, active-controlled period)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>weeks 27-52</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dutogliptin</intervention_name>
    <description>100 mg QD</description>
    <arm_group_label>dutogliptin (double-blind, placebo-controlled period)</arm_group_label>
    <arm_group_label>dutogliptin (single-blind, active-controlled period)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dutogliptin</intervention_name>
    <description>200 mg QD</description>
    <arm_group_label>dutogliptin (double-blind, placebo-controlled period)</arm_group_label>
    <arm_group_label>dutogliptin (single-blind, active-controlled period)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo (double-blind, placebo-controlled period)</arm_group_label>
    <arm_group_label>placebo (single-blind, active-controlled period)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin</intervention_name>
    <description>25 mg QD</description>
    <arm_group_label>sitagliptin (single-blind, active-controlled period)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin</intervention_name>
    <description>50 mg QD</description>
    <arm_group_label>sitagliptin (single-blind, active-controlled period)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus

          -  Renal impairment (moderate and severe)

          -  Currently on stable doses of background medication of SU, TZD, acarbose, meglitinide,
             insulin or any combination thereof, or on no antidiabetic drugs at all

          -  HbA1c 7.0% - 10.5%, inclusive

          -  Male or female subjects between the ages of 18 and 85 years, inclusive.

        Exclusion Criteria:

          -  Type 1 diabetes mellitus or history of diabetic ketoacidosis, mature onset diabetes of
             the young (MODY)

          -  Kidney transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Phenomix Investigational Site 115</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 121</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 110</name>
      <address>
        <city>Lynwood</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 118</name>
      <address>
        <city>Lynwood</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 119</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 109</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 122</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 112</name>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 104</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 116</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 101</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 117</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 102</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 100</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 125</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 114</name>
      <address>
        <city>Springfield Gardens</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 120</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 107</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 111</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 103</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 106</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 108</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 113</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 208</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 203</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 204</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 209</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 211</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 205</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 207</name>
      <address>
        <city>Perm.</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 206</name>
      <address>
        <city>Petrozavodsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 200</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 201</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 210</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 212</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 213</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 304</name>
      <address>
        <city>Chernivtsi</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 300</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 301</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 306</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 302</name>
      <address>
        <city>Odesa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 303</name>
      <address>
        <city>Vinnytsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phenomix Investigational Site 307</name>
      <address>
        <city>Zaporizhzhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2009</study_first_submitted>
  <study_first_submitted_qc>August 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2009</study_first_posted>
  <last_update_submitted>February 1, 2010</last_update_submitted>
  <last_update_submitted_qc>February 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>Hans-Peter Guler, MD</name_title>
    <organization>Phenomix Corporation</organization>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>DPP4 inhibitor</keyword>
  <keyword>dutogliptin</keyword>
  <keyword>PHX1149</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

